Literature DB >> 6703368

Continuous infusion epidural analgesia in parturients receiving bupivacaine, chloroprocaine, or lidocaine--maternal, fetal, and neonatal effects.

T K Abboud, A Afrasiabi, F Sarkis, F Daftarian, S Nagappala, R Noueihed, B R Kuhnert, F Miller.   

Abstract

The effects of epidural analgesia for labor and delivery using a continuous infusion technique on fetal heart rate, uterine activity, maternal blood pressure, Apgar scores, neonatal acid-base status, and the Neurologic and Adaptive Capacity Scoring System were studied in 61 parturients. Group I (n = 23) received initial test and therapeutic doses of 2 and 6 ml of 0.5% bupivacaine followed by an infusion of 0.125% at a rate of 14 ml/hr. Group II (n = 19) received 2 and 6 ml of 2% chloroprocaine followed by an infusion of 0.75% at a rate of 27 ml/hr. Group III (n = 19) received 2 and 6 ml of 1.5% lidocaine followed by an infusion of 0.75% at a rate of 14 ml/hr. None of the three local anesthetics used had any significant effect on baseline fetal heart rate or uterine activity. In cases in which monitoring of fetal heart rate was both technically satisfactory and continuous, late and variable decelerations in fetal heart rate were seen in 10 of 17, 3 of 18, and 2 of 19 of the fetuses in groups I, II, and III, respectively. The incidence was significantly higher in group I than in groups II or III (P less than 0.05). Apgar scores and neonatal acid-base status were equally good in all three groups. Neurologic and adaptive capacity scores did not differ among the three groups of neonates, nor did any of the neonates in the three groups score lower than a control group of 19 neonates whose mothers did not receive any analgesia or medications for labor and delivery.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703368

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  11 in total

Review 1.  Fetal monitoring and neonatal resuscitation: what the anaesthetist should know.

Authors:  J Guay
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 2.  Controversies in obstetric anaesthesia.

Authors:  K G Smedstad
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

3.  Continuous infusion epidural analgesia for obstetrics: bupivacaine versus bupivacaine-fentanyl mixture.

Authors:  R D Elliott
Journal:  Can J Anaesth       Date:  1991-04       Impact factor: 5.063

Review 4.  Adverse effects and drug interactions associated with local and regional anaesthesia.

Authors:  M Naguib; M M Magboul; A H Samarkandi; M Attia
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

Review 5.  Update on obstetrical anaesthesia.

Authors:  D Biehl; R J Palahniuk
Journal:  Can Anaesth Soc J       Date:  1986-03

6.  Maternal positioning affects fetal heart rate changes after epidural analgesia for labour.

Authors:  R Preston; E T Crosby; D Kotarba; H Dudas; R D Elliott
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

7.  Circulatory stability and plasma lidocaine levels during continuous and intermittent thoracic epidural analgesia.

Authors:  M Kawamoto; A Sera; H Tanaka; H Niinai
Journal:  J Anesth       Date:  1991-04       Impact factor: 2.078

8.  A comparative study of patient controlled epidural analgesia (PCEA) and continuous infusion epidural analgesia (CIEA) during labour.

Authors:  D R Gambling; P Yu; C Cole; G H McMorland; L Palmer
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

9.  A comparative study of continuous and intermittent epidural analgesia for labour and delivery.

Authors:  K G Smedstad; D H Morison
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

10.  Placental transfer of lidocaine hydrochloride after prolonged continuous maternal intravenous administration.

Authors:  M Banzai; S Sato; N Tezuka; H Komiya; T Chimura; M Hiroi
Journal:  Can J Anaesth       Date:  1995-04       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.